Team
Drug Development & Clinical Team
Professor of Metabolic Biology, UC Berkeley (formerly Harvard/MGH). 25+ years in transcriptional regulation, miRNA biology, and metabolic disease. Pioneer in LNA ASO mixmer therapeutics. Inventor on multiple patents.
Extensive experience with preclinical studies focusing on metabolic homeostasis and therapeutic approaches targeting metabolic dysfunction.
Executive Director, Solve FSHD. Extensive neuromuscular drug development experience from preclinical through human Phase 1/2 trials at Pfizer, Cytokinetics, and NMD Pharma.
Extensive oligo CMC and drug development experience, serving as consultant for numerous drug and biotech companies.
Extensive LNA ASO drug development experience from BMS, Wave Life Sciences, and Deep Genomics.
Cardiology Clinical Research Director and Advanced Heart Failure Comprehensive Care Center Chief at UCSF.
Scientific, Strategic & Regulatory Advisors
CEO and Founder, Kimia Therapeutics. Co-founder of multiple biotech companies, including Carmot Therapeutics (acquired by Roche for $2.7B).
Former Partner at The Column Group. Extensive experience in biotech and venture capital, board member at multiple biotech startups.
Professor at UCSD School of Medicine, Dept. of Cellular & Molecular Medicine. Specializes in RNAi therapeutics. Biotech founder, serves on SABs for biotechs and pharma.
Executive Director, UC Berkeley Molecular Therapeutics Initiative and founding Director of the UC Berkeley Drug Discovery Center. 10+ years industry experience, 5+ molecules in the clinic.
RegenMed Advisors, LLC. Regulatory strategy and FDA guidance for advanced therapeutics.
Woodward Consulting, LLC. 20 years early-stage life science consulting. 10 years Partner, Ventac Partners A/S. Variety of life science CxO roles.